Findings
emesis, nausea
NASOPHARYNGEAL CARCINOMA, SECONDARY
In this randomized clinical trial of 100 patients with nasopharyngeal carcinoma, there was no significantly significant difference in cumulative risk of emesis or rescue therapy in patients receiving weekly fosaprepitant compared with those receiving fosaprepitant every 3 weeks. Patients who received fosaprepitant weekly were less likely to experience emesis and nausea, a secondary outcome of the trial.